PRESS RELEASE published on 11/01/2024 at 13:52, 19 days 23 hours ago Liquidity Agreement and Total Voting Rights Novacyt provides liquidity agreement update and total voting rights information, with Invest Securities purchasing and selling ordinary shares. Company divided into clinical, instrumentation, and research use segments Ordinary Shares Liquidity Agreement Total Voting Rights Novacyt Clinical Diagnostics
BRIEF published on 10/31/2024 at 10:28, 21 days 2 hours ago Le Dr Ian Gilham rejoint Novacyt en tant que directeur non exécutif Nomination Au Conseil D'administration Sciences De La Vie Novacyt Administrateur Non Exécutif Dr Ian Gilham
BRIEF published on 10/31/2024 at 10:28, 21 days 2 hours ago Dr. Ian Gilham Joins Novacyt as Non-Executive Director Life Sciences Board Appointment Non-Executive Director Novacyt Dr. Ian Gilham
BRIEF published on 10/31/2024 at 10:25, 21 days 2 hours ago Appointment of Dr Ian Gilham to the Board of Directors of Novacyt Board Of Directors Life Sciences Appointment Novacyt Ian Gilham
BRIEF published on 10/31/2024 at 10:25, 21 days 2 hours ago Nomination du Dr Ian Gilham au Conseil d'Administration de Novacyt Conseil D'administration Nomination Sciences De La Vie Novacyt Ian Gilham
PRESS RELEASE published on 10/31/2024 at 10:23, 21 days 2 hours ago Directorate Change Novacyt appoints Dr Ian Gilham as Non-Executive Director, bringing expertise in life sciences companies to strengthen the Board Life Sciences Non-Executive Director Novacyt Dr Ian Gilham AIM-listed
PRESS RELEASE published on 10/31/2024 at 10:20, 21 days 2 hours ago Changement au Conseil d’Administration Nomination du Dr Ian Gilham au poste d’administrateur non exécutif chez Novacyt. Son expertise renforcera le conseil d'administration de la société Conseil D'administration Santé Diagnostic Moléculaire Novacyt Dr Ian Gilham
BRIEF published on 10/17/2024 at 11:47, 1 month 4 days ago Certification IVDR pour le test Yourgene® de la mucoviscidose par Novacyt Dépistage Novacyt IVDR Mucoviscidose Yourgene
BRIEF published on 10/17/2024 at 11:47, 1 month 4 days ago IVDR Certification for Yourgene® Cystic Fibrosis Test by Novacyt Screening Novacyt IVDR Cystic Fibrosis Yourgene
PRESS RELEASE published on 10/17/2024 at 11:42, 1 month 4 days ago Certification IVDR obtenue pour le test de référence Yourgene® de la mucoviscidose Novacyt obtient la certification IVDR pour le test de mucoviscidose Yourgene®. Le test est conforme aux normes de qualité et de sécurité européennes, essentiel pour le dépistage de la mucoviscidose Dépistage Novacyt Mucoviscidose Yourgene Certification IVDR
Published on 11/21/2024 at 12:00, 59 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 59 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 29 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 2 hours 56 minutes ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 2 hours 59 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 24 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 44 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 29 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 1 minute ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 1 minute ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 1 minute ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 52 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 39 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
